(NASDAQ: RNAC) Cartesian Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.59%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.49%.
Cartesian Therapeutics's earnings in 2025 is -$42,518,000.On average, 5 Wall Street analysts forecast RNAC's earnings for 2025 to be -$86,946,875, with the lowest RNAC earnings forecast at -$101,740,821, and the highest RNAC earnings forecast at -$71,374,300. On average, 3 Wall Street analysts forecast RNAC's earnings for 2026 to be -$105,374,421, with the lowest RNAC earnings forecast at -$116,794,310, and the highest RNAC earnings forecast at -$86,946,875.
In 2027, RNAC is forecast to generate -$153,389,860 in earnings, with the lowest earnings forecast at -$153,389,860 and the highest earnings forecast at -$153,389,860.